Patheon to participate at 2010 Bio International Convention

RESEARCH TRIANGLE PARK, N.C., April 29 /CNW/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry invites customers, potential customers and representatives of the media to visit Patheon's booth number 1757 to learn more about the comprehensive service offerings and specialized capabilities it provides to the biopharmaceutical industry.

Patheon employee Roman Hlodan, who has authored an article that will be published in the May 2010 issue of BioPharm International will attend the convention, as well as other executives from the company. Mr. Hloden's article discusses the unique advantages of working with companies such as Patheon for biotechnology companies looking for a strategic outsourcing partner.

Patheon serves six of the world's 10 largest biotechnology customers and it is currently developing 11 of the top 100 developmental stage drugs in the world on behalf of our customers.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech and provides insights and inspiration on the major trends in the industry today.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

For further information: Patheon Contacts: Wes Wheeler, President & Chief Executive Officer, Tel: [phone], Email: [email protected]; Eric Evans, Chief Financial Officer, Tel: [phone], Email: [email protected]; Wendy Wilson, Investor Relations and Corporate Communications, Tel: [phone], Email: [email protected]